Ashling Wahner

Articles

FDA Approves Danicopan as Add-On Therapy for Extravascular Hemolysis in PNH

April 1st 2024

The FDA has approved danicopan as add-on therapy to ravulizumab or eculizumab for extravascular hemolysis in paroxysmal nocturnal hemoglobinuria.

UTD1 Receives FDA Orphan Drug Designation in Breast Cancer Brain Metastasis

April 1st 2024

Utidelone injectable has received FDA orphan drug designation for patients with breast cancer brain metastases.

Rezatapopt Revolutionizes Research Directions in TP53-Mutated Solid Tumors

March 29th 2024

Shivaani Kummar, MBBS, FACP, discusses the mechanism of action of the TP53-directed agent rezatapopt and efficacy data with this agent in solid tumors.

Observational Study Shows Frontline Ibrutinib With/Without Rituximab Is Safe and Effective in Low-Risk Mantle Cell Lymphoma

March 28th 2024

Ibrutinib with or without rituximab was effective and tolerable in patients with previously untreated, low-risk mantle cell lymphoma.

China’s NMPA Accepts sNDA for Savolitinib in Locally Advanced/Metastatic MET Exon 14+ NSCLC

March 28th 2024

China’s NMPA has accepted an sNDA for approval of savolitinib for treatment-naive locally advanced/metastatic NSCLC with MET exon 14 skipping alterations.

Retrospective Study Shows HSCT Consolidation After Blast Reduction Improves OS in Chronic Phase–Reverted MPN

March 27th 2024

Patients with myeloproliferative neoplasms in accelerated or blast phase experience improved survival outcomes after hematopoietic cell transplantation.

SLS009 Generates Positive Topline Data in R/R AML and REGAL Trial Completes Enrollment

March 26th 2024

Positive phase 2a topline findings have been announced with SLS009 plus azacitidine and venetoclax in relapsed/refractory acute myeloid leukemia.

Momelotinib Efficacy Propels the Future Development of JAK Inhibitors in Myelofibrosis

March 25th 2024

Joseph G. Jurcic, MD, highlights findings from the phase 3 SIMPLIFY-1, SIMPLIFY-2, and MOMENTUM trials in myelofibrosis.

Next-Generation JAK Inhibitors Signal the Future of Myelofibrosis Treatment Advances

March 22nd 2024

Joseph G. Jurcic, MD, discusses the benefits and limitations of several JAK inhibitors for patients with myelofibrosis.

Ide-Cel Receives EU Approval for Triple Class–Exposed R/R Multiple Myeloma

March 21st 2024

The European Commission has approved idecabtagene vicleucel for triple-class–exposed relapsed/refractory multiple myeloma.

Experts Share Top Highlights from the 2024 SGO Annual Meeting on Women’s Cancer

March 19th 2024

From key sessions at the 2024 SGO Annual Meeting to updates in the field, gynecologic oncology experts share their key takeaways from the meeting.

Revisit the OncLive On Air Episodes From February 2024

March 18th 2024

In case you missed it, read a recap of every episode of OncLive On Air recorded in February 2024.

Graff Highlights the Importance of Perseverance and Self-Advocacy as a Woman in Oncology

March 15th 2024

Stephanie L. Graff, MD, shares her journey to becoming an oncologist, advice for work-life balance, and ways to confront gender bias in medicine.

Phase 1 Trial of IMM-1-104 Generates Positive Topline Results in RAS-Mutant Solid Tumors

March 14th 2024

Initial antitumor activity and safety data have been observed in the phase 1 portion of a phase 1/2a trial of IMM-1-104 in RAS-mutant solid tumors.

TERN-701 Receives FDA Orphan Drug Designation in CML

March 12th 2024

TERN-701 has received orphan drug designation from the FDA for the treatment of patients with chronic myeloid leukemia.

Community/Academic Research Collaboration Paves the Way for Improved Cancer Care

March 11th 2024

Gautam Jha, MD, and Emmanuel Antonarakis, MD, discuss the ins and outs of clinical trial partnerships between community and academic cancer centers.

MRD Testing Presents Challenges and Opportunities in Breast Cancer Care

March 10th 2024

Heather McArthur, MD, MPH, discusses the prognostic benefits of circulating tumor DNA and limitations that prevent these results from being predictive.

HER2-Directed Therapies Continue to Shape Improved Breast Cancer Outcomes

March 10th 2024

Debu Tripathy, MD, provides insights on the management of HER2-positive breast cancer, including the evolving role of trastuzumab in this population.

Targeted Agents Expand the HR+/HER2– Metastatic Breast Cancer Treatment Arena

March 9th 2024

Erica Stringer-Reasor, MD, highlights the evolution of therapies for patients with hormone receptor–positive, HER2-negative metastatic breast cancer.

Neoadjuvant Chemotherapy Has Led to De-Escalation of Breast Cancer Surgery and Radiation

March 8th 2024

Terry P. Mamounas, MD, MPH, FACS, discusses treatment options after neoadjuvant chemotherapy and how neoadjuvant chemotherapy influences axillary surgery.